Global Water Resources Declares Monthly Dividend PHOENIX, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share). The dividend will be payable on February 27, 2026, to holders of record at the close of business on February 13, 2026. About Global Water Resources Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 sys...
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 cli...
Global Water Resources Declares Monthly Dividend PHOENIX, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share). The dividend will be payable on January 30, 2026, to holders of record at the close of business on January 16, 2026. About Global Water Resources Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 syste...
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified G...
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA – End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-...
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classifie...
Global Water Resources Declares Monthly Dividend PHOENIX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share). The dividend will be payable on December 30, 2025, to holders of record at the close of business on December 16, 2025. About Global Water Resources Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 sys...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Off...
Global Water Resources Appoints Christa Steele to Board of Directors PHOENIX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has appointed to its board of directors, effective January 1, 2026. She succeeds Debra G. Coy who, as previously announced, will resign from the board at the end of the year to dedicate time to family and pursue other interests. Following the appointment of Steele and the resignation of Coy, the board will continue to be comprised of seven directors, with four serving as independent dire...
Global Water Resources Reports Third Quarter 2025 Results PHOENIX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the third quarter and nine months ended September 30, 2025. Unless otherwise noted, all comparisons are to the corresponding period in the prior year. The company will hold a conference call at 1:00 p.m. Eastern time tomorrow to discuss the results (see dial-in information below). Financial Highlights Total revenue increased 8.4% to $15.5 million for the third quarter of 2025 ...
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer - - Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 - - New...
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at 4:30 pm ET - NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that the company will report third quarter 2025 financ...
Global Water Resources Declares Monthly Dividend PHOENIX, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share). The dividend will be payable on November 26, 2025, to holders of record at the close of business on November 12, 2025. About Global Water Resources Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 sys...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.